Precision Medicine and Big DataThe Application of an Ethics Framework for Big Data in Health and Research

被引:0
作者
G. Owen Schaefer
E Shyong Tai
Shirley Sun
机构
[1] Yong Loo Lin School of Medicine,Centre for Biomedical Ethics
[2] Saw Swee Hock School of Public Health,undefined
[3] Division of Endocrinology,undefined
[4] Sociology,undefined
[5] School of Social Sciences and Lee Kong Chian School of Medicine,undefined
来源
Asian Bioethics Review | 2019年 / 11卷
关键词
Precision medicine; Big data; Bioethics; Genomics; Genetic discrimination;
D O I
暂无
中图分类号
学科分类号
摘要
As opposed to a ‘one size fits all’ approach, precision medicine uses relevant biological (including genetic), medical, behavioural and environmental information about a person to further personalize their healthcare. This could mean better prediction of someone’s disease risk and more effective diagnosis and treatment if they have a condition. Big data allows for far more precision and tailoring than was ever before possible by linking together diverse datasets to reveal hitherto-unknown correlations and causal pathways. But it also raises ethical issues relating to the balancing of interests, viability of anonymization, familial and group implications, as well as genetic discrimination. This article analyses these issues in light of the values of public benefit, justice, harm minimization, transparency, engagement and reflexivity and applies the deliberative balancing approach found in the Ethical Framework for Big Data in Health and Research (Xafis et al. 2019) to a case study on clinical genomic data sharing. Please refer to that article for an explanation of how this framework is to be used, including a full explanation of the key values involved and the balancing approach used in the case study at the end. Our discussion is meant to be of use to those involved in the practice as well as governance and oversight of precision medicine to address ethical concerns that arise in a coherent and systematic manner.
引用
收藏
页码:275 / 288
页数:13
相关论文
共 58 条
[1]  
Bayer R(2015)Public health in the precision-medicine era New England Journal of Medicine 373 499-501
[2]  
Galea S(2017)PCSK9 inhibitors: a new era of lipid lowering therapy World Journal of Cardiology 9 76-1678
[3]  
Chaudhary R(2014)Delivering precision medicine in oncology today and in future—the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO) Annals of Oncology 25 1673-1272
[4]  
Garg J(2006)Sequence variations in PCSK9, low LDL, and protection against coronary heart disease New England Journal of Medicine 354 1264-1407
[5]  
Shah N(2012)Investigating the potential for ethnic group harm in collaborative genomics research in Africa: is ethnic stigmatisation likely? Social Science & Medicine 75 1400-694
[6]  
Sumner A(2018)Identity inference of genomic data using long-range familial searches Science 362 690-659
[7]  
Ciardiello F(2015)Precision medicine: at what price? American Journal of Respiratory and Critical Care Medicine 192 658-642
[8]  
Arnold D(2012)Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research Genetics in Medicine 14 633-399
[9]  
Casali PG(2015)GINA, genetic discrimination, and genomic medicine New England Journal of Medicine 372 397-2219
[10]  
Cervantes A(2017)Proprotein convertase subtilisin/kexin type 9 inhibitor therapy: payer approvals and rejections, and patient characteristics for successful prescribing Circulation 136 2210-1041